Overton conceded multiple times during the hearing that vaccines approved by the FDA, as well as the so-called “abortion pill ...

Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform ...

Telix paid $165 billion upfront primarily to secure ITM’s lead radioligand candidate ITM-11, which was recently rejected by ...

Roche’s Genentech is paying Earendil Labs $55 million upfront to discover and develop multiple bispecific antibodies. The ...

The National Institutes of Health's National Library of Medicine has released the pilot version of a new tool designed to ...

Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug ...

Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their ...

Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover ...

Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up ...

Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go ...

Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers (TCEs).

ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public ...